Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats

Melissa J. Karau; Suzannah M. Schmidt-Malan; Qun Yan; Kerryl E. Greenwood-Quaintance; Jayawant Mandrekar; Dario Lehoux; Raymond Schuch; Cara Cassino; Robin Patel

doi:10.1128/AAC.01122-19

Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats

Melissa J. Karau, Suzannah M. Schmidt-Malan, Qun Yan, Kerryl E. Greenwood-Quaintance, Jayawant Mandrekar, Dario Lehoux, Raymond Schuch, Cara Cassino, Robin Patel

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Bacteriophage-derived lysins are being developed as anti-infective agents. In an acute osteomyelitis methicillin-resistant Staphylococcus aureus (MRSA) model, rats receiving no treatment or treatment with daptomycin, exebacase (CF-301), or daptomycin plus exebacase had means of 5.13, 4.09, 4.65, and 3.57 log₁₀ CFU/gram of bone, respectively. All treated animals had fewer bacteria than did untreated animals (P≤ 0.0001), with daptomycin plus exebacase being more active than daptomycin (P= 0.0042) or exebacase (P < 0.001) alone.

Original language	English (US)
Article number	e01235-19
Journal	Antimicrobial Agents and Chemotherapy
Volume	63
Issue number	10
DOIs	https://doi.org/10.1128/AAC.01122-19
State	Published - 2019

Keywords

CF-301
Daptomycin
Exebacase
Methicillin-resistant Staphylococcus aureus
Osteomyelitis

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Access to Document

10.1128/AAC.01122-19

Cite this

Karau, M. J., Schmidt-Malan, S. M., Yan, Q., Greenwood-Quaintance, K. E., Mandrekar, J., Lehoux, D., Schuch, R., Cassino, C., & Patel, R. (2019). Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats. Antimicrobial Agents and Chemotherapy, 63(10), Article e01235-19. https://doi.org/10.1128/AAC.01122-19

Karau, MJ, Schmidt-Malan, SM, Yan, Q, Greenwood-Quaintance, KE, Mandrekar, J, Lehoux, D, Schuch, R, Cassino, C & Patel, R 2019, 'Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats', Antimicrobial Agents and Chemotherapy, vol. 63, no. 10, e01235-19. https://doi.org/10.1128/AAC.01122-19

@article{078b93040260416e8a20c5301c6bc1f9,

title = "Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats",

abstract = "Bacteriophage-derived lysins are being developed as anti-infective agents. In an acute osteomyelitis methicillin-resistant Staphylococcus aureus (MRSA) model, rats receiving no treatment or treatment with daptomycin, exebacase (CF-301), or daptomycin plus exebacase had means of 5.13, 4.09, 4.65, and 3.57 log10 CFU/gram of bone, respectively. All treated animals had fewer bacteria than did untreated animals (P≤ 0.0001), with daptomycin plus exebacase being more active than daptomycin (P= 0.0042) or exebacase (P < 0.001) alone.",

keywords = "CF-301, Daptomycin, Exebacase, Methicillin-resistant Staphylococcus aureus, Osteomyelitis",

author = "Karau, {Melissa J.} and Schmidt-Malan, {Suzannah M.} and Qun Yan and Greenwood-Quaintance, {Kerryl E.} and Jayawant Mandrekar and Dario Lehoux and Raymond Schuch and Cara Cassino and Robin Patel",

year = "2019",

doi = "10.1128/AAC.01122-19",

language = "English (US)",

volume = "63",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "10",

}

TY - JOUR

T1 - Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats

AU - Karau, Melissa J.

AU - Schmidt-Malan, Suzannah M.

AU - Yan, Qun

AU - Greenwood-Quaintance, Kerryl E.

AU - Mandrekar, Jayawant

AU - Lehoux, Dario

AU - Schuch, Raymond

AU - Cassino, Cara

AU - Patel, Robin

PY - 2019

Y1 - 2019

N2 - Bacteriophage-derived lysins are being developed as anti-infective agents. In an acute osteomyelitis methicillin-resistant Staphylococcus aureus (MRSA) model, rats receiving no treatment or treatment with daptomycin, exebacase (CF-301), or daptomycin plus exebacase had means of 5.13, 4.09, 4.65, and 3.57 log10 CFU/gram of bone, respectively. All treated animals had fewer bacteria than did untreated animals (P≤ 0.0001), with daptomycin plus exebacase being more active than daptomycin (P= 0.0042) or exebacase (P < 0.001) alone.

AB - Bacteriophage-derived lysins are being developed as anti-infective agents. In an acute osteomyelitis methicillin-resistant Staphylococcus aureus (MRSA) model, rats receiving no treatment or treatment with daptomycin, exebacase (CF-301), or daptomycin plus exebacase had means of 5.13, 4.09, 4.65, and 3.57 log10 CFU/gram of bone, respectively. All treated animals had fewer bacteria than did untreated animals (P≤ 0.0001), with daptomycin plus exebacase being more active than daptomycin (P= 0.0042) or exebacase (P < 0.001) alone.

KW - CF-301

KW - Daptomycin

KW - Exebacase

KW - Methicillin-resistant Staphylococcus aureus

KW - Osteomyelitis

UR - http://www.scopus.com/inward/record.url?scp=85072563069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072563069&partnerID=8YFLogxK

U2 - 10.1128/AAC.01122-19

DO - 10.1128/AAC.01122-19

M3 - Article

C2 - 31358593

AN - SCOPUS:85072563069

SN - 0066-4804

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 10

M1 - e01235-19

ER -

Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this